Loading
MICSI-RMT is FDA-cleared software from MICSI that cleans noise out of MRI scans. It is used on brain and prostate scans, including to look for prostate cancer and to plan brain tumour surgery.
MICSI-RMT is the first product of MICSI (Microstructure Imaging, Inc.), radiological image-processing software cleared by the FDA through 510(k) K241121, decided substantially equivalent on 17 July 2024, for MRI image quality enhancement. MICSI's NCI SBIR award states a fourfold signal-to-noise improvement; the clearance is for image enhancement, not for a cancer diagnosis.
Removes noise from MRI data with random matrix theory (Marchenko-Pastur principal component analysis), using the redundancy within the scan rather than training data.
| Region | Year | Indication |
|---|---|---|
| US | 2024 | MRI image quality enhancement (FDA 510(k) K241121, cleared 17 July 2024) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MICSI-RMT" OR ABSTRACT:"MICSI-RMT") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MICSI-RMT, not a curated reading list.
Shares MRI and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/